Company intelligence / Profile preview

Daiwa Securities

Chiyoda-ku, Tokyo, Japanus.daiwacm.com ↗

Ownership: Private
Employees: ~16000
Development stage: Other

Overview

Daiwa Securities is one of Japan’s largest independent investment banks and securities brokerages. It does not develop drugs or medical devices but invests in biotech and healthcare startups through its venture capital arms. Its funds have supported projects in regenerative medicine, oligonucleotide therapeutics, cancer diagnostics, and coronavirus drug development. Clinical results pertain to portfolio companies rather than Daiwa itself.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculesOligonucleotidesRegenerative medicine
Industry: Investors

Partnerships

Joint ventures with Sumitomo Bank/Sumitomo Mitsui Banking Corporation (historically)Investment relationships with government-affiliated entities and institutional investors for biotech funds

Beyond the preview

Go deeper on Daiwa Securities.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Daiwa Securities.

Explore the full profile